Kwangdong Pharmaceutical disclosed its 2025 corporate governance report, revealing governance status and key compliance indicators.
In February 2026, the board resolved a new shareholder return policy: utilize at least 15% of separate net income for shareholder returns, and pay a minimum dividend of KRW 100 per share if net income exceeds KRW 20 billion.
For FY2025, a year-end dividend of KRW 100 per share (total KRW 4.97 billion) was decided. In November 2024, the company also acquired 800,000 treasury shares (approx. KRW 4.43 billion) to expand shareholder returns.
The board consists of 3 inside and 3 outside directors, with audit and ESG committees (newly established) composed entirely of outside directors. However, the CEO also chairs the board, and cumulative voting or a lead independent director system has not been adopted.
A formal CEO succession policy is not documented, and individual evaluation and compensation policies for outside directors are not separately established.
A risk factor: In October 2025, the company withdrew decisions to issue exchangeable bonds and dispose treasury shares, resulting in designation as an unfair disclosure entity and a fine of KRW 12 million.
On internal control, the company holds integrated ISO 37001 (anti-bribery) and ISO 37301 (compliance management) certifications, and operates an internal accounting management system and anonymous reporting system.
[AI Comprehensive Analysis]This governance report shows an overall stable governance structure, but lack of a CEO succession policy, outside director evaluation system, and prior unfair disclosure remain improvement points. The new shareholder return policy is positive but not aggressive enough to create immediate stock momentum.